Dermatomyositis
Identifieur interne : 002392 ( Main/Exploration ); précédent : 002391; suivant : 002393Dermatomyositis
Auteurs : R. M. Trüeb [Suisse]Source :
- Dermatologic Therapy [ 1396-0296 ] ; 2001-06.
Abstract
ABSTRACT: Dermatomyositis (DM) is an acquired, inflammatory muscle disorder of unknown etiology characterized by symmetrical proximal muscle weakness, inflammatory myositis on biopsy, elevation of serum muscle enzymes, abnormal electromyogram, and a typical rash, with or without internal organ involvement. Untreated muscle disease can produce severe and long‐term disabilities, and the cutaneous lesions can cause considerable discomfort from intractable pruritus. A prompt and usually aggressive approach to therapy is indicated, with each patient's management depending on the severity of the skin and muscle disease and the presence or absence of multisystem involvement. The mainstay of therapy for DM is the use of systemic corticosteroids. In those patients that do not respond to steroids or develop significant steroid‐related side effects, immunosuppressive agents (methotrexate, azathioprine, cyclophosphamide, and more recently cyclosporine), or intravenous immunoglobulin (IVIG) are used. General measures include bed rest, passive range‐of‐motion exercises, and active physical therapy. Overall the use of corticosteroids with or without immunosuppressive agents has significantly reduced mortality and increased functional recovery. Corticosteroids may not control the rash. In these cases aminoquinolone antimalarials have been advocated, though partial improvement is more common than complete control. Emollients and photoprotection are essential. In recalcitrant cases of cutaneous DM, low‐dose methotrexate and IVIG have been used with success. Finally, with the recognition of distinct subsets limited to the skin (e.g., amyopathic DM), the dermatologist is confronted with the decision for appropriate therapeutic modalities tailored to the individual patient's needs.
Url:
DOI: 10.1046/j.1529-8019.2001.014002070.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000308
- to stream Istex, to step Curation: 000308
- to stream Istex, to step Checkpoint: 001218
- to stream Main, to step Merge: 002417
- to stream Main, to step Curation: 002392
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dermatomyositis</title><author><name sortKey="Trueb, R M" sort="Trueb, R M" uniqKey="Trueb R" first="R. M." last="Trüeb">R. M. Trüeb</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:31D107C3BE666F2F6C0875A8EA04626CA80D4E15</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1046/j.1529-8019.2001.014002070.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-C6XZCG1Z-Z/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000308</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000308</idno><idno type="wicri:Area/Istex/Curation">000308</idno><idno type="wicri:Area/Istex/Checkpoint">001218</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001218</idno><idno type="wicri:Area/Main/Merge">002417</idno><idno type="wicri:Area/Main/Curation">002392</idno><idno type="wicri:Area/Main/Exploration">002392</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Dermatomyositis</title><author><name sortKey="Trueb, R M" sort="Trueb, R M" uniqKey="Trueb R" first="R. M." last="Trüeb">R. M. Trüeb</name><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Department of Dermatology, University Hospital of Zurich, Zurich</wicri:regionArea><wicri:noRegion>Zurich</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Dermatologic Therapy</title><title level="j" type="alt">DERMATOLOGIC THERAPY</title><idno type="ISSN">1396-0296</idno><idno type="eISSN">1529-8019</idno><imprint><biblScope unit="vol">14</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="70">70</biblScope><biblScope unit="page" to="80">80</biblScope><biblScope unit="page-count">11</biblScope><publisher>Blackwell Science Inc</publisher><pubPlace>Boston, MA, USA</pubPlace><date type="published" when="2001-06">2001-06</date></imprint><idno type="ISSN">1396-0296</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1396-0296</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">ABSTRACT: Dermatomyositis (DM) is an acquired, inflammatory muscle disorder of unknown etiology characterized by symmetrical proximal muscle weakness, inflammatory myositis on biopsy, elevation of serum muscle enzymes, abnormal electromyogram, and a typical rash, with or without internal organ involvement. Untreated muscle disease can produce severe and long‐term disabilities, and the cutaneous lesions can cause considerable discomfort from intractable pruritus. A prompt and usually aggressive approach to therapy is indicated, with each patient's management depending on the severity of the skin and muscle disease and the presence or absence of multisystem involvement. The mainstay of therapy for DM is the use of systemic corticosteroids. In those patients that do not respond to steroids or develop significant steroid‐related side effects, immunosuppressive agents (methotrexate, azathioprine, cyclophosphamide, and more recently cyclosporine), or intravenous immunoglobulin (IVIG) are used. General measures include bed rest, passive range‐of‐motion exercises, and active physical therapy. Overall the use of corticosteroids with or without immunosuppressive agents has significantly reduced mortality and increased functional recovery. Corticosteroids may not control the rash. In these cases aminoquinolone antimalarials have been advocated, though partial improvement is more common than complete control. Emollients and photoprotection are essential. In recalcitrant cases of cutaneous DM, low‐dose methotrexate and IVIG have been used with success. Finally, with the recognition of distinct subsets limited to the skin (e.g., amyopathic DM), the dermatologist is confronted with the decision for appropriate therapeutic modalities tailored to the individual patient's needs.</div></front></TEI><affiliations><list><country><li>Suisse</li></country></list><tree><country name="Suisse"><noRegion><name sortKey="Trueb, R M" sort="Trueb, R M" uniqKey="Trueb R" first="R. M." last="Trüeb">R. M. Trüeb</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002392 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002392 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:31D107C3BE666F2F6C0875A8EA04626CA80D4E15
|texte= Dermatomyositis
}}
| This area was generated with Dilib version V0.6.33. |  |